Cenicriviroc/tropifexor - Allergan/Novartis
Alternative Names: CVC/LJN452; LJC-242; Tropifexor/Cenicriviroc - Novartis/AllerganLatest Information Update: 24 Jan 2023
At a glance
- Originator Novartis
- Developer AbbVie; Novartis
- Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antiretrovirals; Benzothiazoles; Hepatoprotectants; Imidazoles; Oxazoles; Small molecules
- Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists; Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 24 Jan 2023 Cenicriviroc/tropifexor is still in phase II trial in Non-alcoholic steatohepatitis in USA, Belgium, Czech Republic, France, Germany, Italy, Latvia, Portugal, Singapore, Spain, the UK, Argentina, Canada, Egypt, India, Israel, Russia and Turkey (PO)
- 06 May 2021 Novartis announces intention to submit regulatory applications for Non-alcoholic steatohepatitis in or after 2025
- 13 Oct 2020 Novartis and AbbVie complete the TANDEM phase II trial in Non-alcoholic steatohepatitis in USA, Belgium, Czech Republic, France, Germany, Italy, Latvia, Portugal, Singapore, Spain, the UK, Argentina, Canada, Egypt, India, Israel, Russia and Turkey (PO) (NCT03517540) (EudraCT2017-004208-24)